TY - JOUR
T1 - Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors
AU - on behalf of the HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Morishima, Satoko
AU - Fukuda, Takahiro
AU - Doki, Noriko
AU - Mori, Takehiko
AU - Onizuka, Makoto
AU - Kawakita, Toshihiro
AU - Kato, Chiaki
AU - Ozawa, Yukiyasu
AU - Tanaka, Masatsugu
AU - Kurokawa, Mineo
AU - Kamimura, Tomohiko
AU - Inoue, Masami
AU - Tanaka, Junji
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Morishima, Yasuo
AU - Ikegame, Kazuhiro
AU - Utsunomiya, Atae
AU - Kato, Shunichi
AU - Kawase, Takakazu
AU - Kanda, Junya
AU - Kanda, Yoshinobu
AU - Kim, Sung Won
AU - Kobayashi, Takeshi
AU - Takatsuka, Yoshifusa
AU - Takahashi, Yoshiyuki
AU - Tamaki, Hiroya
AU - Tsuji, Masanori
AU - Nishida, Tetsuya
AU - Maeda, Yoshinobu
AU - Masuko, Masayoshi
AU - Matsuno, Ryosuke
AU - Murata, Makoto
AU - Yokoyama, Hisayuki
AU - Wake, Atsushi
AU - Watanabe, Nobuhiro
AU - Ashida, Takashi
AU - Takanashi, Minoko
AU - Hoshino, Takumi
AU - Yabe, Toshio
AU - Sakamoto, Kana
AU - Fuji, Shigeo
AU - Miyamura, Koichi
AU - Arima, Nobuyoshi
AU - Kondo, Eisei
AU - Kawamura, Koji
AU - Kawata, Takahito
AU - Kishimoto, Kenji
AU - Tatara, Raine
AU - Hagino, Takeshi
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/3
Y1 - 2021/3
N2 - In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the effects of patient and donor human leukocyte antigen (HLA) matching status on graft-versus-host disease (GVHD) have been extensively elucidated, but the effects of specific HLAs on acute GVHD remain unclear. Using data from a Japanese registry, we retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from HLA-identical sibling donors to investigate the effects of HLAs on acute GVHD. From unbiased searches of HLA-A, -B, and -DR, HLA-B60 was significantly associated with an increased risk of grades II–IV acute GVHD (HR, 1.34; 95% CI, 1.13–1.59; P = 0.001). In contrast, HLA-B62 was significantly associated with a decreased risk of grades II–IV (HR, 0.73; 95% CI, 0.62–0.87; P < 0.001) and III–IV acute GVHD (HR, 0.63; 95% CI, 0.46–0.87; P = 0.005). The risk of leukemia relapse was significantly higher in HLA-B62-positive patients than in HLA-B62-negative patients (HR, 1.23; 95% CI, 1.05–1.43; P = 0.01). Both HLA-B60 and -B62 did not affect overall survival. The findings of this study may by implication suggest the possibility that the effects of specific HLAs on transplant outcomes may reflect inherent biological features, and thus consideration of specific HLAs may be helpful to predict transplant outcomes.
AB - In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the effects of patient and donor human leukocyte antigen (HLA) matching status on graft-versus-host disease (GVHD) have been extensively elucidated, but the effects of specific HLAs on acute GVHD remain unclear. Using data from a Japanese registry, we retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from HLA-identical sibling donors to investigate the effects of HLAs on acute GVHD. From unbiased searches of HLA-A, -B, and -DR, HLA-B60 was significantly associated with an increased risk of grades II–IV acute GVHD (HR, 1.34; 95% CI, 1.13–1.59; P = 0.001). In contrast, HLA-B62 was significantly associated with a decreased risk of grades II–IV (HR, 0.73; 95% CI, 0.62–0.87; P < 0.001) and III–IV acute GVHD (HR, 0.63; 95% CI, 0.46–0.87; P = 0.005). The risk of leukemia relapse was significantly higher in HLA-B62-positive patients than in HLA-B62-negative patients (HR, 1.23; 95% CI, 1.05–1.43; P = 0.01). Both HLA-B60 and -B62 did not affect overall survival. The findings of this study may by implication suggest the possibility that the effects of specific HLAs on transplant outcomes may reflect inherent biological features, and thus consideration of specific HLAs may be helpful to predict transplant outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85092370640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092370640&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01070-3
DO - 10.1038/s41409-020-01070-3
M3 - Article
C2 - 33037403
AN - SCOPUS:85092370640
SN - 0268-3369
VL - 56
SP - 646
EP - 654
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 3
ER -